Published in Curr Oncol on October 01, 2011
Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality. PLoS One (2014) 0.88
Prioritizing strategies for comprehensive liver cancer control in Asia: a conjoint analysis. BMC Health Serv Res (2012) 0.88
Predictors of mortality in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Dig Dis Sci (2014) 0.86
Hepatitis C virus infection and the rising incidence of hepatocellular carcinoma. Mayo Clin Proc (2012) 0.84
Expanded use of aggressive therapies improves survival in early and intermediate hepatocellular carcinoma. HPB (Oxford) (2014) 0.83
Canadian trends in liver cancer: a brief clinical and epidemiologic overview. Curr Oncol (2013) 0.80
The clinical effect and relevant mechanism of combined sorafenib and radiofrequency ablation in the treatment of early small hepatocellular carcinoma. Oncol Lett (2016) 0.77
Hepatocellular carcinoma: Consensus, controversies and future directions. A report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting. Can J Gastroenterol Hepatol (2015) 0.77
The International College of Neuropsychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 1: Background and Methods of the Development of Guidelines. Int J Neuropsychopharmacol (2016) 0.75
The Evolution of the Use of Serum Alpha-fetoprotein in Clinical Liver Cancer Surveillance. J Immunobiol (2016) 0.75
The importance of a multidisciplinary approach to hepatocellular carcinoma. J Multidiscip Healthc (2017) 0.75
The Geography of Primary Hepatic Neoplasms Treatments in Canada: Changes in Latitudes and Changes in Attitudes. Can J Gastroenterol Hepatol (2017) 0.75
Cost-effectiveness analysis of potentially curative and combination treatments for hepatocellular carcinoma with person-level data in a Canadian setting. Cancer Med (2017) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Management of hepatocellular carcinoma: an update. Hepatology (2011) 33.57
Management of hepatocellular carcinoma. Hepatology (2005) 27.42
Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology (2007) 26.78
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med (1996) 22.46
The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology (2005) 15.74
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet (2002) 12.16
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology (2003) 11.55
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology (2002) 9.76
Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology (2008) 8.24
Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology (2008) 6.75
The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut (2009) 6.50
Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology (2009) 5.87
Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis (2010) 5.85
Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology (1999) 5.70
Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology (2009) 5.68
A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg (2006) 5.65
Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol (2004) 5.29
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol (2009) 4.82
Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA (2010) 4.71
Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology (2008) 4.61
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol (2001) 4.46
Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut (2001) 4.12
Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology (2005) 3.95
Terminology of nodular hepatocellular lesions. Hepatology (1995) 3.87
One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg (2003) 3.84
Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol (2006) 3.65
Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology (2009) 3.57
Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology (2003) 2.90
Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev (2007) 2.75
Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology (2011) 2.66
Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology (2010) 2.61
Heat shock proteins: endogenous modulators of apoptotic cell death. Biochem Biophys Res Commun (2001) 2.56
Epidemiology of hepatocellular carcinoma in USA. Hepatol Res (2007) 2.56
Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology (2009) 2.51
Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis (2010) 2.46
Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology (2009) 2.25
Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol (1994) 2.20
What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge. Oncology (Williston Park) (2011) 2.12
Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int (2008) 2.10
Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. J Gastroenterol Hepatol (2001) 2.06
A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg (2009) 1.97
Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology (2000) 1.95
Chaperones in cell cycle regulation and mitogenic signal transduction: a review. Cell Prolif (2000) 1.90
Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology (2003) 1.85
MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology (2003) 1.85
Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas. Oncogene (2006) 1.84
Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology (2007) 1.81
Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology (1995) 1.76
Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy. Hepatology (1999) 1.73
Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology (1990) 1.72
A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology (2010) 1.64
Meta-analysis of dysphagia and aspiration pneumonia in frail elders. J Dent Res (2011) 1.63
Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. Br J Surg (1995) 1.58
Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer (1996) 1.57
Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol (2009) 1.50
Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol (2010) 1.49
Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. J Am Coll Surg (2008) 1.44
Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg (2011) 1.44
Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterol (2010) 1.41
Improved survival with screening for hepatocellular carcinoma. Liver Transpl (2000) 1.37
Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol (2006) 1.32
Overexpression of glutamine synthetase in human primary liver cancer. Gastroenterology (1994) 1.28
Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl (2004) 1.26
Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol (2006) 1.26
Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant (2008) 1.26
Optimization of imaging diagnosis of 1-2 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization. J Hepatol (2010) 1.24
Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci (2007) 1.24
A prospective randomized trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma. Jpn J Cancer Res (1996) 1.23
Resection of hepatocellular carcinoma without preoperative tumor biopsy. Ann Surg (2001) 1.23
Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol (2010) 1.22
Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol (2008) 1.20
Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: a prospective randomized study. Semin Oncol (1997) 1.19
Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation. Ann Surg Oncol (2008) 1.18
Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study. Gastroenterology (1995) 1.17
Ultrasound follow-up of patients at risk for hepatocellular carcinoma: results of a prospective study on 360 cases. Am J Gastroenterol (1996) 1.14
Hepatocellular carcinoma incidence trends in Canada: analysis by birth cohort and period of diagnosis. Liver Int (2008) 1.13
De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation (2007) 1.11
Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol (2008) 1.06
Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma. J Gastroenterol (2007) 1.06
Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis. Liver Int (2010) 1.05
The current role of neoadjuvant/adjuvant/chemoprevention therapy in partial hepatectomy for hepatocellular carcinoma: a systematic review. Hepatobiliary Pancreat Dis Int (2009) 1.03
An evidence-based multidisciplinary approach to the management of hepatocellular carcinoma (HCC): the Alberta HCC algorithm. Can J Gastroenterol (2010) 1.00
Glypican-3 expression in benign liver tissue with active hepatitis C: implications for the diagnosis of hepatocellular carcinoma. Hum Pathol (2007) 0.99
The place of downstaging for hepatocellular carcinoma. J Hepatol (2010) 0.95
Contrast enhancement of small hepatocellular carcinoma: usefulness of three successive early image acquisitions during multiphase dynamic MR imaging. AJR Am J Roentgenol (1999) 0.92
Sonographic screening for hepatocellular carcinoma in patients with chronic hepatitis or cirrhosis: an evaluation. AJR Am J Roentgenol (1998) 0.91
Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutations. J Clin Oncol (2011) 0.90
Small nodules (1-2 cm) in liver cirrhosis: characterization with contrast-enhanced ultrasound. Eur J Radiol (2008) 0.88
Results of liver transplantation: with or without Milan criteria? Liver Transpl (2007) 0.88
Hepatocellular carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2008) 0.85
Uses and limitations of portal vein embolization for improving perioperative outcomes in hepatocellular carcinoma. Semin Oncol (2010) 0.84
Acquisition of glutamine synthetase expression in human hepatocarcinogenesis: relation to disease recurrence and possible regulation by ubiquitin-dependent proteolysis. Cancer (1999) 0.82
The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature (1997) 34.00
The complete genome sequence of the hyperthermophilic, sulphate-reducing archaeon Archaeoglobus fulgidus. Nature (1997) 14.38
Polarity of Tn5 insertion mutations in Escherichia coli. J Bacteriol (1980) 7.55
The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell (1991) 6.13
The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL 2 production reflects events occurring at a pre-translational level. J Immunol (1984) 5.80
The role of the T3/antigen receptor complex in T-cell activation. Annu Rev Immunol (1986) 5.67
ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain. Cell (1992) 5.53
Requirement for the coexpression of T3 and the T cell antigen receptor on a malignant human T cell line. J Exp Med (1984) 5.26
Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science (1991) 5.12
Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptor. Cell (1992) 5.08
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol (2001) 4.89
Role of T3 surface molecules in human T-cell activation: T3-dependent activation results in an increase in cytoplasmic free calcium. Proc Natl Acad Sci U S A (1984) 4.66
In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers. J Exp Med (2000) 4.37
Sequential interactions of the TCR with two distinct cytoplasmic tyrosine kinases. Science (1994) 4.23
Induction of NF-kappaB by the Akt/PKB kinase. Curr Biol (1999) 4.03
Characterization of two adhesins of Bordetella pertussis for human ciliated respiratory-epithelial cells. J Infect Dis (1985) 3.66
Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. N Engl J Med (1996) 3.63
Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature (1995) 3.40
LAT is required for TCR-mediated activation of PLCgamma1 and the Ras pathway. Immunity (1998) 3.36
The role of protein tyrosine kinases and protein tyrosine phosphatases in T cell antigen receptor signal transduction. Annu Rev Immunol (1994) 3.35
Prenatal management of 746 pregnancies at risk for congenital toxoplasmosis. N Engl J Med (1988) 3.15
Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet (1994) 3.10
Changes in conserved region 2 of Escherichia coli sigma 70 affecting promoter recognition. J Mol Biol (1990) 3.04
Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S A (2001) 3.04
Tyrosine phosphorylation of vav proto-oncogene product containing SH2 domain and transcription factor motifs. Nature (1992) 3.02
Uncoupling of nonreceptor tyrosine kinases from PLC-gamma1 in an SLP-76-deficient T cell. Science (1998) 2.93
The trans-neptunian object UB313 is larger than Pluto. Nature (2006) 2.88
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol (2002) 2.87
Signal transduction by the TCR for antigen. Curr Opin Immunol (2000) 2.87
Urinary leukocyte esterase screening test for asymptomatic chlamydial and gonococcal infections in males. JAMA (1989) 2.87
Reconstitution of an active surface T3/T-cell antigen receptor by DNA transfer. Nature (1985) 2.84
How easy is it to contact the duty medical doctor responsible for acute admissions? BMJ (1990) 2.80
The zeta chain is associated with a tyrosine kinase and upon T-cell antigen receptor stimulation associates with ZAP-70, a 70-kDa tyrosine phosphoprotein. Proc Natl Acad Sci U S A (1991) 2.74
Expression of T3 in association with a molecule distinct from the T-cell antigen receptor heterodimer. Proc Natl Acad Sci U S A (1986) 2.73
ZAP-70 deficiency in an autosomal recessive form of severe combined immunodeficiency. Science (1994) 2.71
Antigen cap formation in cultured fibroblasts: a reflection of membrane fluidity and of cell motility. Proc Natl Acad Sci U S A (1972) 2.71
Human severe combined immunodeficiency due to a defect in ZAP-70, a T cell tyrosine kinase. Science (1994) 2.70
Mitochondrial DNA molecules and virtual number of mitochondria per cell in mammalian cells. J Cell Physiol (1988) 2.59
PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression. J Biol Chem (2000) 2.57
Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFN-gamma but not TH2 cytokines. Nat Immunol (2001) 2.55
The T cell antigen receptor complex expressed on normal peripheral blood CD4-, CD8- T lymphocytes. A CD3-associated disulfide-linked gamma chain heterodimer. J Exp Med (1987) 2.52
Tyrosine phosphatase CD45 is essential for coupling T-cell antigen receptor to the phosphatidyl inositol pathway. Nature (1990) 2.51
The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. Hum Mol Genet (1996) 2.45
Tyrosine phosphatase CD45 is required for T-cell antigen receptor and CD2-mediated activation of a protein tyrosine kinase and interleukin 2 production. Proc Natl Acad Sci U S A (1991) 2.45
Activation of a human T cell line: a two-stimulus requirement in the pretranslational events involved in the coordinate expression of interleukin 2 and gamma-interferon genes. J Immunol (1985) 2.39
Expression and function of the CD3-antigen receptor on murine CD4+8+ thymocytes. Nature (1987) 2.38
A 275 basepair fragment at the 5' end of the interleukin 2 gene enhances expression from a heterologous promoter in response to signals from the T cell antigen receptor. J Exp Med (1987) 2.37
Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol (1998) 2.36
Antibiotic resistance as a stress response: complete sequencing of a large number of chromosomal loci in Staphylococcus aureus strain COL that impact on the expression of resistance to methicillin. Microb Drug Resist (1999) 2.35
Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. J Clin Invest (1998) 2.35
Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene (1997) 2.32
Long-term follow-up of survivors of acute lung injury: lack of effect of a ventilation strategy to prevent barotrauma. Crit Care Med (1999) 2.29
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat (2014) 2.23
Distinct subsets of CD1d-restricted T cells recognize self-antigens loaded in different cellular compartments. J Exp Med (1999) 2.23
The immunological synapse and CD28-CD80 interactions. Nat Immunol (2001) 2.23
A light and electron microscopic analysis of gentamicin nephrotoxicity in rats. Am J Pathol (1976) 2.23
Nonspecific bronchial reactivity in occupational asthma. J Allergy Clin Immunol (1979) 2.22
Steady-state end-tidal alveolar dead space fraction and D-dimer: bedside tests to exclude pulmonary embolism. Chest (2001) 2.22
Presence of Ti (WT31) negative T lymphocytes in normal blood and thymus. Nature (1987) 2.20
Vav and SLP-76 interact and functionally cooperate in IL-2 gene activation. Immunity (1996) 2.18
Functional characterization of a signal transducing motif present in the T cell antigen receptor zeta chain. J Exp Med (1993) 2.17
Molecular characterization of a common fragile site (FRA7H) on human chromosome 7 by the cloning of a simian virus 40 integration site. Proc Natl Acad Sci U S A (1998) 2.16
Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. EMBO J (1995) 2.14
The antigen receptor on a human T cell line initiates activation by increasing cytoplasmic free calcium. J Immunol (1985) 2.13
Specific antigen-Ia activation of transfected human T cells expressing murine Ti alpha beta-human T3 receptor complexes. Nature (1987) 2.11
Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol (1994) 2.10
c-Src regulates the simultaneous rearrangement of actin cytoskeleton, p190RhoGAP, and p120RasGAP following epidermal growth factor stimulation. J Cell Biol (1995) 2.06
Traumatic subarachnoid-pleural fistula. Ann Thorac Surg (1996) 2.05
Physician-assisted suicide: a care option for dying patients? Nephrol News Issues (1996) 2.02
Perfusion monitoring during radical perineal prostatectomy. Anesthesiology (1997) 2.01
An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity. Cell (2000) 2.00
Lck regulates the tyrosine phosphorylation of the T cell receptor subunits and ZAP-70 in murine thymocytes. J Exp Med (1996) 1.98
The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellular loading of HLA-A2. J Immunol (1991) 1.96
Role of VraSR in antibiotic resistance and antibiotic-induced stress response in Staphylococcus aureus. Antimicrob Agents Chemother (2006) 1.94
T cell activation: differences in the signals required for IL 2 production by nonactivated and activated T cells. J Immunol (1985) 1.94
T cell antigen receptor signal transduction. Curr Opin Cell Biol (1997) 1.92
XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer (2011) 1.90
A model system for activation-induced alternative splicing of CD45 pre-mRNA in T cells implicates protein kinase C and Ras. Mol Cell Biol (2000) 1.90
Recovery of Bordetella pertussis from four kinds of swabs. Eur J Clin Microbiol (1987) 1.89
SarT, a repressor of alpha-hemolysin in Staphylococcus aureus. Infect Immun (2001) 1.89
ZAP-70 is constitutively associated with tyrosine-phosphorylated TCR zeta in murine thymocytes and lymph node T cells. Immunity (1994) 1.88
A functional T-cell receptor signaling pathway is required for p95vav activity. Mol Cell Biol (1995) 1.88
Cytoskeletal polarization of T cells is regulated by an immunoreceptor tyrosine-based activation motif-dependent mechanism. J Cell Biol (1998) 1.85
Early signal transduction by the antigen receptor without commitment to T cell activation. Science (1988) 1.85
The mouse CD1d-restricted repertoire is dominated by a few autoreactive T cell receptor families. J Exp Med (2001) 1.85
Development and optimization of cytokine ELISAs using commercial antibody pairs. J Immunol Methods (2001) 1.83
CD28 mediates transcriptional upregulation of the interleukin-2 (IL-2) promoter through a composite element containing the CD28RE and NF-IL-2B AP-1 sites. Mol Cell Biol (1997) 1.83
Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men. Genitourin Med (1996) 1.82
Injuries of the spine sustained during rugby. Sports Med (1988) 1.82
Interobserver variation in interpreting chest radiographs for the diagnosis of acute respiratory distress syndrome. Am J Respir Crit Care Med (2000) 1.81
Identification of the minimal tyrosine residues required for linker for activation of T cell function. J Biol Chem (2001) 1.81
The Syk family of protein tyrosine kinases in T-cell activation and development. Immunol Rev (1998) 1.81
Identification and sequence of a fourth human T cell antigen receptor chain. Nature (1988) 1.81
Differential expression of ZAP-70 and Syk protein tyrosine kinases, and the role of this family of protein tyrosine kinases in TCR signaling. J Immunol (1994) 1.80
An immunodeficiency characterized by defective signal transduction in T lymphocytes. N Engl J Med (1989) 1.79
alpha beta T cell development is abolished in mice lacking both Lck and Fyn protein tyrosine kinases. Immunity (1996) 1.79
Ligand-mediated negative regulation of a chimeric transmembrane receptor tyrosine phosphatase. Cell (1993) 1.78
Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution. J Clin Oncol (1994) 1.75
T cell receptor signalling. J Cell Sci (2001) 1.74